Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    22009536 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Unknown  Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy
Conditions: Hematologic Malignancy;   Acute Lymphocytic Leukemia;   Chronic Lymphocytic Leukemia;   Myelodysplasia;   Acute Myeloid Leukemia;   Chronic Myelogenous Leukemia;   Hodgkin's Disease
Intervention: Drug: Ciclopirox Olamine

Indicates status has not been verified in more than two years